Since the first antiviral drug, idoxuridine, was approved in 1963, 90 antiviral drugs
categorized into 13 functional groups have been formally approved for the treatment of the …

Small molecules that bind to the viral capsid protein can be potent inhibitors of HIV infection.
Capsid-targeting drugs are predicted to exhibit high barriers to viral resistance, and ongoing …

Oral antiretroviral agents provide life-saving treatments for millions of people living with HIV,
and can prevent new infections via pre-exposure prophylaxis,,,–. However, some people …

The HIV genome encodes a small number of viral proteins (ie, 16), invariably establishing
cooperative associations among HIV proteins and between HIV and host proteins, to invade …

Background The HIV pandemic is characterized by extensive genetic variability, which has
challenged the development of HIV drugs and vaccines. Although HIV genomes have been …

Human immunodeficiency virus type 1 (HIV-1) infection depends on efficient
intracytoplasmic transport of the incoming viral core to the target cell nucleus. Evidence …

The human immunodeficiency virus type 1 (HIV-1) capsid plays crucial roles in HIV-1
replication and thus represents an excellent drug target. We developed a high-throughput …

Background: The infectious human immunodeficiency virus (HIV) particle is characterized by
a conical capsid that encloses the viral RNA genome. The capsid is essential for HIV-1 …

Recently reported HIV-1 capsid (CA) inhibitors GS-CA1 and GS-6207 (an analog of GS-
CA1) are first-in-class compounds with long-acting potential. Reportedly, both compounds …

Combined HIV antiretroviral therapy (cART) has been effective except if drug resistance
emerges. As cART has been rolled out in low-income countries, drug resistance has …